|
|
|
|
 |
SAN DIEGO--- Akesis Pharmaceuticals Names Christos Mantzoros, MD, Dsc to its Scientific Advisory Board |
| 7/18/2008 @ 3:50 PM
print this article -
email to a friend -
join our eNewsletter
|
 |
Akesis Pharmaceuticals, Inc. (OTCBB: AKES), an emerging metabolic disease drug development company, today announced it has appointed Christos Mantzoros, MD, Dsc, to its scientific advisory board (SAB). Dr. Mantzoros is an Associate Professor of Medicine at Harvard Medical School and an Associate Professor in Epidemiology at the Harvard School of Public Health. He serves as the Clinical Research Overseer of the Division of Endocrinology Diabetes and Metabolism at Beth Israel Deaconess Medical Center and the Joslin Diabetes Center in Boston, and is a member of the Executive Committee of the Scholars in Clinical Science Program, a postgraduate clinical investigators training program at Harvard Medical School.
“We are extremely pleased that Christos Mantzoros agreed to join our SAB. I look forward to interacting with him as we evaluate the potential of AKP-020 in the diabetic setting and as we begin to expand our metabolic disease drug candidate pipeline,” stated Carl LeBel, Ph.D., Akesis’ President and Chief Operating Officer.
Dr. Mantzoros obtained an MD and Dsc from the University of Athens Medical School, a Master's in Clinical Epidemiology from Harvard School of Public Health and a Master’s in Medical Sciences (Clinical Investigation) from Harvard Medical School. He has received Board certification in Internal Medicine, Endocrinology, Diabetes and Metabolism and in Clinical Nutrition.
Dr. Mantzoros is an internationally recognized expert on obesity and diabetes, and has published two books (“Diabetes and Obesity” and “Nutrition and Metabolism”), more than 200 original papers, more than 90 chapters and reviews, and has received more than 9,000 citations. He serves on the editorial board of several journals, including the Journal of Clinical Endocrinology and Metabolism.
With this appointment Dr. Mantzoros joins an Akesis SAB currently comprised of University of British Columbia researchers Chris Orvig, Ph.D., professor of chemistry and pharmaceutical sciences, and John McNeill, Ph.D., professor and dean emeritus, pharmaceutical sciences, as well as Michael Scaife, Ph.D., biopharmaceutical industry veteran and expert in regulatory affairs and product development. Professors Orvig and McNeill, who are experts in the study of metal chemistry and pharmaceutical sciences are the inventors of AKP-020, the product designation for a novel vanadium compound otherwise known as bis(ethylmaltolato)oxovanadium (IV), or BEOV. AKP-020 is licensed exclusively to Akesis and is currently being evaluated in Phase 2 studies for the potential treatment of type 2 diabetes mellitus.
About Akesis Pharmaceuticals
Akesis Pharmaceuticals has a pipeline of innovative oral product candidates for the treatment of diabetes and related metabolic disorders. These product candidates are supported by issued and filed U.S. patents for both prescription and over-the-counter treatments that combine anti-diabetic trace minerals with certain classes of diabetes oral agents. Akesis' product candidates have demonstrated preliminary evidence of efficacy in lowering and controlling blood glucose levels in patients with Type 2 diabetes. Blood sugar control via oral drugs represents a market opportunity in the billions of dollars, as reports indicate that approximately 20 million people suffer from diabetes in the United States alone. More information can be found at www.akesis.com. |
| Tech People On the Move - California |
|
|
| |
| Friday, September 5, 2008 |
 |
|
CARLSBAD--- Invitrogen Names Joe Beery Senior Vice President, Chief Information Officer Posted 7:26 AM PST
|
| |
| Thursday, September 4, 2008 |
|
|
SAN JOSE--- Intel’s Ken Tallo Elected Chair of the Open SystemC Initiative Posted 3:22 PM PST
OAKLAND--- Scientific Learning Chief Financial Officer to Depart Company Posted 3:12 PM PST
SAN JOSE--- Mark Carges Joins eBay To Lead Global Platform Development Posted 7:40 AM PST
WALNUT CREEK--- WildPackets Taps Industry Veteran Jim Laird as Vice President of Sales Posted 7:39 AM PST
SAN DIEGO--- DriveCam Announces Brandon Nixon as New CEO Posted 7:37 AM PST
|
| |
| Wednesday, September 3, 2008 |
|
|
EL DORADO HILLS--- Board Member Bob Lamvik to Join SAI Executive Staff as Chief Operating Officer Posted 3:16 PM PST
SAN DIEGO--- Qualcomm Appoints Robert Walton Senior Vice President and Division President of Qualcomm Enterprise Services Posted 3:09 PM PST
REDWOOD CITY--- Genelabs Technologies, Inc. Announces Appointment of Frederick W. Driscoll as President and CEO Posted 3:00 PM PST
LOS ANGELES--- Aqua Connect Inc. Appoints Paul Fiore to its Board of Directors Posted 6:30 AM PST
CARLSBAD--- Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors Posted 6:29 AM PST
|
| |
| Tuesday, September 2, 2008 |
|
|
LOS GATOS--- Netflix Appoints Bill Holmes as V.P. of Business Development Posted 5:01 PM PST
SAN JOSE--- SunPower Promotes Howard Wenger to President, Global Business Units Posted 9:10 AM PST
SAN DIEGO--- Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives Posted 8:40 AM PST
SAN MATEO--- Composite Software Appoints VP of Alliances Posted 8:39 AM PST
PALO ALTO--- MyProductAdvisor.com Appoints New President Posted 8:34 AM PST
SAN FRANCISCO--- BitTorrent Appoints New Vps to its Management Team Posted 8:30 AM PST
SAN DIEGO--- Zhu Shen of BioForesight Joins Editorial Advisory Board of PharmAsia News Posted 8:10 AM PST
|
| |
| Friday, August 29, 2008 |
|
|
EL SEGUNDO--- Internet Brands Appoints Scott Friedman CFO Posted 2:38 PM PST
REDWOOD CITY--- Gary Read, President and CEO of Nimsoft, Appointed to Board of Directors of Scalable Software Posted 8:44 AM PST
SAN DIEGO--- Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Senior Vice President, Regulatory Affairs and Quality Assurance Posted 8:35 AM PST
SANTA CLARA--- GSI Technology, Inc. Announces New Director Posted 8:24 AM PST
|
| |
| Thursday, August 28, 2008 |
|
|
MILPITAS--- KLA-Tencor Appoints Mark P. Dentinger New Chief Financial Officer Posted 2:56 PM PST
MILPITAS--- President and COO John Kispert to Leave KLA-Tencor Posted 2:55 PM PST
|
| |
| Tuesday, August 26, 2008 |
|
|
LOS ANGELES--- Anodyne Medical Device, Inc. Announces Abbey Daniels as New Chief Executive Officer Posted 3:37 PM PST
SAN DIEGO--- Prometheus Announces New Chief Financial Officer Posted 8:49 AM PST
SAN MATEO--- Quantivo Appoints High-Tech Veterans to Executive Team Posted 8:36 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
